Table 1 Study participant characteristics
From: Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy
HIV- (n = 13) | PWH, Baseline (n = 35) | PWH, Week 48 (n = 35) | P-Values | |
|---|---|---|---|---|
Age | 43 (23–58) | 43 (23–58) | 44 (24–59) | P = 0.98 |
HIV Viral Load (copies/mL) | NA | 37,153 (6637-619,797) | 48 (48–48) | |
CD4+ T cell (cells/mL) | NR | 259 (1–599) | 489 (87–1026) | |
Sex (%) | Male = 10 (77%) | Male = 32 (91%) | P = 0.32 | |
Female = 3 (23%) | Female = 3 (9%) | |||
Ethnicity (%) | White = 9 (69%) | White = 18 (52%) | P = 0.35 | |
Not White = 4 (31%) | Not White = 12 (34%) | |||
Hispanic = 5 (14%) | ||||
Total Cholesterol (mg/dL) | 185 (93–266) | 125 (87–208) | 142 (93–226) | P < 0.001, HIV- v BL |
P = 0.005, HIV- v Wk48 | ||||
P = 0.004, BL v Wk48 | ||||
LDL (mg/dL) | 100 (34–176) | 73 (51–154) | 84 (45–164) | P = 0.02, HIV- v BL |
P = 0.17, HIV- v Wk48 | ||||
P = 0.02, BL v Wk48 | ||||
HDL (mg/dL) | 57 (41–103) | 35 (0–56) | 41 (17–71) | P < 0.001, HIV- v BL |
P < 0.001, HIV- v Wk48 | ||||
P = 0.004, BL v Wk48 | ||||
Triglycerides (mg/dL) | 89 (62–205) | 72 (36–162) | 87 (30–200) | P = 0.48, HIV- v BL |
P = 0.95, HIV- v Wk48 | ||||
P = 0.34, BL v Wk48 | ||||
Lipoprotein Insulin Resistance (LPIR) score | 42 (1–70) | 52 (10–77) | 53 (10–86) | P = 0.06, HIV- v BL |
P = 0.2, HIV- v Wk48 | ||||
P = 0.42, BL v Wk48 | ||||
Adiponectin (ng/mL) | NR | 4281 (558–14,652) | 3600 (446–8862) | P = 0.1 |
Leptin (pg/mL) | NR | 2412 (325–81,416) | 5856 (486–79,755) | P = 0.06 |
BMI ≥ 25 (%) | NR | 50 | NR |